Julian Christopher Lagoy, MD
Psychiatry · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 4 carriers
- Office
- 1
Offices
1 location · Mark David Levine MD Professional Corporation · 165 clinicians in this group
Looking this up.
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lagoy’s office at (855) 501-1004 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
California Medical Board record
Licence A161713 · Current
Licensed to practise in California · since 2019 · expires 2027-04-30 · St. George'S University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$8,130
Medicare paid this office $8,130 for 17 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 17 | $7,253 | $112 |
Who their Medicare patients are
17 Original Medicare patients in 2024. Average age 62 · Health risk score 1.30. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.
Conditions among them: Depression 75% · High blood pressure 65%.
The office billed $39,771, Medicare allowed $11,404 and paid $8,130; for 71 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$117,289 in 2024
Medicaid paid $117,289 for 478 billed services this clinician did in 2024, up to 47 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 478 | $117,289 |
| 2024 | 478 | 1 | 47 | $117,289 |
| 2023 | 304 | 1 | 34 | $78,180 |
| 2022 | 346 | 1 | 34 | $93,614 |
| 2021 | 293 | 1 | 33 | $78,273 |
| 2020 | 35 | 1 | 15 | $9,481 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 304 | $78,180 |
2022
| Return visit (30+ min) | 346 | $93,614 |
2021
| Return visit (30+ min) | 293 | $78,273 |
2020
| Return visit (30+ min) | 35 | $9,481 |
Drugs they prescribed that Part D paid
$50,251
Pharmacies billed $50,251 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 386) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
373 generic and 13 brand-name prescriptions · $50,251 in drug cost · 43 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Quetiapine | 12 | $2,490 | $207 |
| Aripiprazole | 20 | $1,307 | $65 |
| Divalproex | 14 | $1,031 | $74 |
| Venlafaxine Hcl Er | 15 | $468 | $31 |
| Gabapentin | 25 | $433 | $17 |
See all 14 drugs
| Quetiapine | 12 | $2,490 | $207 |
| Aripiprazole | 20 | $1,307 | $65 |
| Divalproex | 14 | $1,031 | $74 |
| Venlafaxine Hcl Er | 15 | $468 | $31 |
| Gabapentin | 25 | $433 | $17 |
| Clonazepam | 20 | $411 | $21 |
| Bupropion Xl | 14 | $341 | $24 |
| Methylphenidate | 17 | $295 | $17 |
| Duloxetine | 14 | $258 | $18 |
| Sertraline | 30 | $249 | $8 |
| Trazodone | 15 | $173 | $12 |
| Fluoxetine | 13 | $169 | $13 |
| Lorazepam | 27 | $92 | $3 |
| Zolpidem | 16 | $44 | $3 |
Year by year
| 2024 | 386 | 44 | 0% (0) | 3% | $50,251 |
| 2023 | 248 | 36 | 0% (0) | 7% | $57,778 |
| 2022 | 190 | 24 | 0% (0) | 6% | $69,359 |
| 2021 | 110 | 19 | 0% (0) | None | $23,726 |
| 2020 | 49 | 14 | 0% (0) | None | $6,067 |
| 2019 | 53 | 18 | 0% (0) | None | $1,586 |
| 2018 | 428 | 55 | 0% (0) | 3% | $20,186 |
| 2017 | 227 | 47 | 0% (0) | None | $7,398 |
| 2016 | 36 | None | 0% (0) | None | $1,480 |
| 2015 | 71 | 18 | None | 17% | $3,567 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Quetiapine | 12 | $4,725 | $394 |
| Aripiprazole | 22 | $2,054 | $93 |
| Sertraline | 23 | $326 | $14 |
| Lorazepam | 21 | $309 | $15 |
| Lithium Carbonate Er | 11 | $235 | $21 |
| Gabapentin | 12 | $235 | $20 |
| Clonazepam | 14 | $186 | $13 |
2022: 6 drugs
| Aripiprazole | 15 | $831 | $55 |
| Venlafaxine Hcl Er | 13 | $510 | $39 |
| Sertraline | 15 | $354 | $24 |
| Buspirone | 13 | $266 | $20 |
| Lorazepam | 23 | $180 | $8 |
| Trazodone | 11 | $114 | $10 |
2018: 13 drugs
| Duloxetine | 17 | $1,085 | $64 |
| Bupropion Xl | 32 | $1,026 | $32 |
| Quetiapine | 44 | $942 | $21 |
| Mirtazapine | 34 | $760 | $22 |
| Memantine | 19 | $743 | $39 |
| Escitalopram | 38 | $588 | $15 |
| Donepezil | 28 | $484 | $17 |
| Fluoxetine | 20 | $429 | $21 |
| Sertraline | 30 | $328 | $11 |
| Trazodone | 30 | $279 | $9 |
| Risperidone | 17 | $225 | $13 |
| Venlafaxine Hcl Er | 16 | $211 | $13 |
| Buspirone | 17 | $207 | $12 |
2017: 6 drugs
| Quetiapine | 31 | $549 | $18 |
| Escitalopram | 28 | $345 | $12 |
| Mirtazapine | 16 | $204 | $13 |
| Sertraline | 16 | $195 | $12 |
| Trazodone | 19 | $189 | $10 |
| Buspirone | 11 | $91 | $8 |
Money from drug and device companies
$2,116 in 2025
| 2025 | 13 | 93 | None | $2,116 |
| 2024 | 12 | 58 | None | $1,410 |
| 2023 | 12 | 56 | None | $1,298 |
| 2022 | 10 | 47 | None | $1,118 |
| 2021 | 7 | 41 | None | $965 |
| 2020 | 5 | 14 | None | $275 |
| 2019 | 4 | 5 | None | $66 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Vraylar | $505 | 26 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $360 | 18 payments
|
| Otsuka America Pharmaceutical | Rexulti | $252 | 11 payments
|
| Axsome Therapeutics | Auvelity | $251 | 8 payments
|
| Alkermes | Lybalvi | $207 | 9 payments
|
| Janssen Pharmaceuticals | Spravato | $156 | 5 payments
|
See all 93 published payments
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-12-30 | Caplyta | $31 |
| Abbvie | Meals · 2025-12-23 | Vraylar | $21 |
| Axsome Therapeutics | Meals · 2025-12-16 | Auvelity | $32 |
| Abbvie | Meals · 2025-12-11 | Vraylar | $15 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-12-11 | Caplyta | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-09 | Trintellix | $17 |
| Otsuka America Pharmaceutical | Meals · 2025-12-04 | Rexulti | $27 |
| Alkermes | Meals · 2025-12-02 | Aristada | $21 |
| Abbvie | Meals · 2025-11-25 | Vraylar | $28 |
| Abbvie | Meals · 2025-11-18 | Vraylar | $27 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-11-06 | Caplyta | $32 |
| Neurocrine BioSciences | Meals · 2025-11-05 | Ingrezza | $31 |
| Alkermes | Meals · 2025-10-28 | Lybalvi | $28 |
| Lundbeck | Meals · 2025-10-23 | Rexulti | $28 |
| Axsome Therapeutics | Meals · 2025-10-22 | Auvelity | $30 |
| Otsuka America Pharmaceutical | Meals · 2025-10-16 | Rexulti | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-14 | Trintellix | $19 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-10-09 | Caplyta | $34 |
| Abbvie | Meals · 2025-10-08 | Vraylar | $12 |
| Abbvie | Meals · 2025-10-07 | Vraylar | $9 |
| Abbvie | Meals · 2025-10-07 | Vraylar | $23 |
| Abbvie | Meals · 2025-10-01 | Vraylar | $22 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-09-25 | Caplyta | $0 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-09-25 | Caplyta | $4 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-09-25 | Caplyta | $4 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-09-25 | Caplyta | $21 |
| Alkermes | Meals · 2025-09-23 | Aristada | $23 |
| Teva Pharmaceuticals USA | Meals · 2025-09-18 | Austedo Xr | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-16 | Cobenfy | $32 |
| Abbvie | Meals · 2025-09-16 | Vraylar | $3 |
| Otsuka America Pharmaceutical | Meals · 2025-09-11 | Rexulti | $22 |
| Abbvie | Meals · 2025-09-09 | Vraylar | $7 |
| Abbvie | Meals · 2025-09-09 | Vraylar | $32 |
| Abbvie | Meals · 2025-09-02 | Vraylar | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-28 | Cobenfy | $31 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-26 | Caplyta | $29 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-26 | Caplyta | $5 |
| Otsuka America Pharmaceutical | Meals · 2025-08-21 | Rexulti | $19 |
| Janssen Pharmaceuticals | Meals · 2025-08-19 | Spravato | $31 |
| Abbvie | Meals · 2025-08-14 | Vraylar | $24 |
| Lundbeck | Meals · 2025-08-12 | Rexulti | $29 |
| Janssen Pharmaceuticals | Meals · 2025-08-06 | Invega Sustenna | $33 |
| Axsome Therapeutics | Meals · 2025-08-05 | Auvelity | $31 |
| Otsuka America Pharmaceutical | Meals · 2025-07-31 | Rexulti | $29 |
| Alkermes | Meals · 2025-07-29 | Lybalvi | $32 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-07-29 | Caplyta | $13 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-07-21 | Caplyta | $24 |
| Alkermes | Meals · 2025-07-15 | Aristada | $18 |
| Vanda Pharmaceuticals | Meals · 2025-07-15 | Fanapt | $16 |
| Abbvie | Meals · 2025-07-10 | Vraylar | $22 |
| Otsuka America Pharmaceutical | Meals · 2025-07-08 | Abilify Asimtufii | $3 |
| Otsuka America Pharmaceutical | Meals · 2025-07-08 | Abilify Asimtufii | $26 |
| Abbvie | Meals · 2025-06-18 | Vraylar | $7 |
| Abbvie | Meals · 2025-06-13 | Vraylar | $21 |
| Otsuka America Pharmaceutical | Meals · 2025-06-05 | Rexulti | $23 |
| Janssen Pharmaceuticals | Meals · 2025-06-03 | Invega Sustenna | $27 |
| Lundbeck | Meals · 2025-05-30 | Rexulti | $22 |
| Axsome Therapeutics | Meals · 2025-05-28 | Auvelity | $34 |
| Abbvie | Meals · 2025-05-13 | Vraylar | $34 |
| Janssen Pharmaceuticals | Meals · 2025-05-08 | Spravato | $30 |
| Alkermes | Meals · 2025-05-06 | Aristada | $15 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-30 | Caplyta | $34 |
| Lundbeck | Meals · 2025-04-30 | Rexulti | $22 |
| Abbvie | Meals · 2025-04-29 | Vraylar | $17 |
| Abbvie | Meals · 2025-04-24 | Vraylar | $26 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-23 | Caplyta | $23 |
| Otsuka America Pharmaceutical | Meals · 2025-04-22 | Abilify Maintena | $28 |
| Abbvie | Meals · 2025-04-16 | Vraylar | $17 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-16 | Trintellix | $22 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-10 | Caplyta | $11 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-10 | Caplyta | $9 |
| Axsome Therapeutics | Meals · 2025-04-08 | Auvelity | $28 |
| Alkermes | Meals · 2025-04-04 | Lybalvi | $25 |
| Otsuka America Pharmaceutical | Meals · 2025-04-01 | Rexulti | $25 |
| Abbvie | Meals · 2025-03-27 | Vraylar | $28 |
| Tris Pharma | Meals · 2025-03-25 | Dyanavel Xr | $25 |
| Alkermes | Meals · 2025-03-20 | Aristada | $21 |
| Axsome Therapeutics | Meals · 2025-03-18 | Auvelity | $32 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-03-13 | Caplyta | $30 |
| Abbvie | Meals · 2025-03-12 | Vraylar | $16 |
| Janssen Pharmaceuticals | Meals · 2025-03-11 | Spravato | $35 |
| Abbvie | Meals · 2025-03-11 | Vraylar | $10 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-13 | Trintellix | $17 |
| Axsome Therapeutics | Meals · 2025-02-11 | Auvelity | $31 |
| Abbvie | Meals · 2025-02-06 | Vraylar | $28 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-04 | Caplyta | $33 |
| Lundbeck | Meals · 2025-01-30 | Rexulti | $29 |
| Axsome Therapeutics | Meals · 2025-01-29 | Auvelity | $34 |
| Abbvie | Meals · 2025-01-25 | Vraylar | $13 |
| Otsuka America Pharmaceutical | Meals · 2025-01-16 | Rexulti | $21 |
| Tris Pharma | Meals · 2025-01-14 | Dyanavel Xr | $24 |
| Alkermes | Meals · 2025-01-09 | Lybalvi | $24 |
| Abbvie | Meals · 2025-01-02 | Vraylar | $24 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,410
| Abbvie | Vraylar | $400 | 17 payments
|
| Janssen Pharmaceuticals | Spravato | $155 | 6 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $136 | 6 payments
|
| Alkermes | Aristada | $134 | 6 payments
|
| Lundbeck | Rexulti | $126 | 5 payments
|
| Axsome Therapeutics | Auvelity | $111 | 4 payments
|
| Corium | Azstarys | $106 | 4 payments
|
| Supernus Pharmaceuticals | Qelbree | $97 | 4 payments
|
| Vanda Pharmaceuticals | Fanapt | $56 | 2 payments
|
| Tris Pharma | Dyanavel Xr | $49 | 2 payments
|
| Tempus AI | None | $21 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $19 | 1 payment
|
2023: $1,298
| Abbvie | Vraylar | $431 | 20 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $183 | 8 payments
|
| Axsome Therapeutics | Auvelity | $119 | 4 payments
|
| Lundbeck | Abilify Maintena | $88 | 3 payments
|
| Corium | Azstarys | $82 | 5 payments
|
| Vanda Pharmaceuticals | Hetlioz | $81 | 3 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $75 | 3 payments
|
| Iti | Caplyta | $73 | 3 payments
|
| Tris Pharma | Dyanavel Xr | $72 | 3 payments
|
| Supernus Pharmaceuticals | Qelbree | $51 | 2 payments
|
| Alkermes | Aristada | $24 | 1 payment
|
| Otsuka America Pharmaceutical | Nuedexta | $20 | 1 payment
|
2022: $1,118
| Abbvie | Vraylar | $425 | 21 payments
|
| Lundbeck | Rexulti | $130 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $119 | 5 payments
|
| Vanda Pharmaceuticals | Fanapt | $104 | 4 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $101 | 3 payments
|
| Iti | Caplyta | $83 | 3 payments
|
| Corium | Azstarys | $72 | 3 payments
|
| Axsome Therapeutics | Auvelity | $35 | 1 payment
|
| Alfasigma USA | None | $31 | 1 payment
|
| Otsuka America Pharmaceutical | Abilify Maintena | $18 | 1 payment
|
2021: $965
| AbbVie | Vraylar | $330 | 17 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $282 | 9 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $127 | 5 payments
|
| Lundbeck | Rexulti | $120 | 5 payments
|
| Otsuka America Pharmaceutical | Rexulti | $50 | 2 payments
|
| Teva Pharmaceuticals USA | Austedo | $33 | 2 payments
|
| Sunovion Pharmaceuticals | Latuda | $24 | 1 payment
|
2020: $275
| Takeda Pharmaceuticals U.S.A. | Trintellix | $63 | 3 payments
|
| Otsuka America Pharmaceutical | Rexulti | $62 | 3 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $56 | 2 payments
|
| Lundbeck | Rexulti | $50 | 3 payments
|
| Allergan | Vraylar | $44 | 3 payments
|
2019: $66
| Allergan | Vraylar | $27 | 2 payments
|
| Otsuka America Pharmaceutical | Rexulti | $15 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $12 | 1 payment
|
| Arbor Pharmaceuticals | Evekeo Odt | $11 | 1 payment
|
Professional record
- NPI
- 1053706861
- Licence
- CA A161713California A161713: Current · expires 2027-04-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Psychiatry (2084P0800X); Student in a training program (390200000X)
- Mailing address
- 3835 N Freeway Blvd Ste 100, Sacramento, CA, 95834
- NPI first listed
- 2015-03-30
- NPI last updated
- 2026-05-26
- NPI record certified
- 2026-05-26
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1906 Belleview Ave Se, Roanoke, VA, 24014